EVT801
Advanced Solid Tumors
Key Facts
About Kazia Therapeutics
Kazia Therapeutics is a Sydney-based, ASX-listed biotech focused on high-unmet-need oncology. Its mission is to identify and develop differentiated drug candidates, primarily through in-licensing, to address cancers with poor prognoses. The company's lead asset, paxalisib, is a PI3K/mTOR inhibitor with Orphan and Fast Track Designation for glioblastoma, representing a potential new treatment paradigm. Kazia's strategy hinges on generating compelling clinical data to enable regulatory approval, strategic partnerships, or acquisition, operating as a capital-efficient, pipeline-focused entity.
View full company profileOther Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |